| Literature DB >> 36052975 |
Soon Ho Yoon1, Kwon Joong Na2, Chang Hyun Kang2, In Kyu Park2, Samina Park2, Jin Mo Goo1, Young Tae Kim2.
Abstract
Shared decision-making is imperative for patient-and family-centered care. However, gathering individuals in a single place was challenged by modern life and pandemic restrictions. This study conducted a 1:1 randomized trial to examine the feasibility of a CT-derived 3D virtual explanation module for lung cancer to improve the understanding of patients and third parties in physically separate locations. We prospectively enrolled adults in whom elective surgical resection for lung cancer was planned at a single tertiary hospital in 2020. From presurgical CT scans, deep neural networks automatically segmented lung cancer, airway, pulmonary lobes, skin, and bony thorax. The segmented structures were subsequently transformed into an anonymized interactive 3D module which comprised a standardized scenario with explanatory texts. The intervention group received a link to the module on their smartphone before admission and could repeatedly access the link or transfer it to patients' third parties. A total of 33 and 29 patients were enrolled in the intervention and control arms. The understanding score did not statistically differ between the arms (mean difference, 0.7 [95% CI: -0.2, 1.5]; p = 0.13). However, 76% of patients in the intervention arm accessed the link, and patient median access count was 14. The link recipients of third parties had comparable understanding scores to the patients (mean difference, -0.2 [95% CI: -1.9, 1.5]; p = 1.00), indicating that the understanding could be shared remotely with patients and patients' third parties. In conclusion, it was feasible that people physically separated from patients obtained a comparable understanding of lung cancer surgery using the patient's CT-derived 3D virtual explanation module.Entities:
Keywords: 3D understanding; computed tomography; lung cancer
Mesh:
Year: 2022 PMID: 36052975 PMCID: PMC9527161 DOI: 10.1111/1759-7714.14637
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.223
FIGURE 1Study flow diagram
FIGURE 2Representative screenshots in the patient‐specific 3D virtual explanation module
Questionnaire to assess understanding between patients and third parties
| Basic anatomy | |
|---|---|
| 1. The lungs are located in the middle of the chest | True; False; Not sure |
| 2. The lung is a paired organ. | True; False; Not sure |
| 3. One lung can be divided into two or three lobes. | True; False; Not sure |
| 4. There are bronchi and blood vessels inside the lungs. | True; False; Not sure |
|
| |
| 5. Where is lung cancer located? (please choose the largest one, if multiple) | Right upper lobe; Right middle lobe; Right lower lobe; Left upper lobe; Left lower lobe; Not sure |
| 6. What is the size of the lung cancer? | <3 cm; 3‐5 cm; 5‐7 cm; ≥7 cm; Not sure |
| 7. How many lesions are suspected to be lung cancer? | 1; 2; ≥3; Not sure |
|
| |
| 8. Only lung cancer is resected, not its surrounding areas. | True; False; Not sure |
| 9. Surgeons will resect the entire pulmonary lobe that includes lung cancer. | True; False; Not sure |
Baseline characteristics
| Intervention group ( | Control group ( |
| ||
|---|---|---|---|---|
| Age (years) | 62.0 ± 10.2 | 61.4 ± 10.1 | 0.93 | |
| Male | 11 (33%) | 14 (48%) | 0.30 | |
| Multiplicity | Single lesion | 24 (73%) | 23 (79%) | 0.57 |
| Multiple lesions | 9 (27%) | 6 (21%) | ||
| Largest lesion location | Right upper lobe | 8 (24%) | 12 (41%) | 0.01 |
| Right middle lobe | 3 (9%) | 1 (3%) | ||
| Right lower lobe | 5 (15%) | 12 (41%) | ||
| Left upper lobe | 9 (27%) | 3 (10%) | ||
| Left lower lobe | 8 (24%) | 1 (3%) | ||
| Surgery | Lobectomy | 22 (67%) | 21 (69%) | 0.15 |
| Segmentectomy | 7 (21%) | 8 (31%) | ||
| Wedge resection | 4 (12%) | 0 (0%) | ||
| Pathology | Adenocarcinoma | 25 (60%) | 27 (75%) | 0.68 |
| MIA/AIS | 4 (10%) | 3 (8%) | ||
| Squamous | 4 (10%) | 2 (6%) | ||
| Other NSCLC or SCLC | 2 (5%) | 1 (3%) | ||
| Benign lesions | 7 (17%) | 3 (8%) | ||
| Pathological size of the largest lesion (cm) | Total tumor size | 2.5 ± 1.9 | 2.3 ± 1.1 | 0.64 |
| Invasive component | 2.3 ± 2.0 | 2.0 ± 1.3 | 0.92 | |
| Pathological T descriptor | Tmi | 3 (9%) | 2 (7%) | 0.89 |
| T1a | 4 (12%) | 4 (14%) | ||
| T1b | 10 (30%) | 10 (34%) | ||
| T1c | 3 (9%) | 5 (17%) | ||
| T2 | 10 (24%) | 6 (21%) | ||
| T3‐4 | 3 (9%) | 2 (7%) | ||
| Pathological N descriptor | N0 | 27 (82%) | 25 (86%) | 0.40 |
| N1‐2 | 4 (12%) | 4 (14%) | ||
| Nx | 2 (6%) | 0 (0%) |
Abbreviations: AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer.
T, N descriptors were assessed based on the eighth edition of the TNM Classification for Lung Cancer.